Clinical trials: Recurrent Head and Neck Carcinoma
Head and Neck Squamous Cell Carcinoma
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC
This study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy, safety of SYS6010 compared with monotherapy in participants with HNSCC.
- Trial name
- NCT07758621
- Testing
- SYS6010, Investigator's Choice of monotherapy
- Volunteers
- 340 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Recurrent or Metastatic Head and Neck Carcinoma
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
For patients relapsing after platinum-based therapy, few data are available. The current use of cetuximab associated with radiotherapy in localized disease and associated with platinum-based chemotherapy in the first-line setting…
- Trial name
- NCT02347332
- Testing
- Vinflunine, Methotrexate
- Where
- France
- Volunteers
- 459 people
- Sponsor
- Pierre Fabre Medicament
Nasopharyngeal Carcinoma
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have…
- Trial name
- NCT06259721
- Testing
- Anti-PD1 antibody, nimotuzumab and capecitabine
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of Sacituzumab Tirumotecan and Toripalimab in the first-line treatment of recurrent/metastatic head and neck…
- Trial name
- NCT07088211
- Testing
- Sacituzumab Tirumotecan and Toripalimab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Cancer
Thalidomide in Treating Patients With Thyroid Cancer
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
- Trial name
- NCT00026533
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Kenneth Ain
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
This phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has…
- Trial name
- NCT05799144
- Testing
- DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Michael K. Gibson
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01612546
- Testing
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Esophageal Neoplasms
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
- Trial name
- NCT03787251
- Testing
- Apatinib, The chemotherapeutic drug chosen by the investigator.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02196168
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in…
- Trial name
- NCT00102635
- Testing
- Fenretinide (4-HPR), SCH66336
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
This is a single-arm, non-randomized pilot study to evaluate the efficacy and tolerability of combination quad-shot palliative radiotherapy with immunotherapy for advanced/recurrent/metastatic head and neck cancer.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04454489
- Testing
- Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Thermotherapy in Addition to SOC Palliative Radiotherapy
This study aims to investigate the efficacy and safety profile of superficial hyperthermia (wIRA) in addition to standard of care (SOC) palliative radiotherapy in patients with inoperable/incurable locally advanced or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Breast Cancer Recurrent
- Trial name
- ThermoRad wIRA (NCT06659146)
- Testing
- Superficial hyperthermia
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College London
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05726370
- Testing
- Pembrolizumab, CISPLATIN, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
This phase I trial studies the side effects and best dose of giving everolimus (RAD001) and erlotinib hydrochloride together with radiation therapy in treating patients with recurrent head and neck cancer previously treated with…
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01332279
- Testing
- everolimus, erlotinib hydrochloride, biopsy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
NSCLC, HNSCC
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- Trial name
- TACTI-002 (NCT03625323)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Immutep S.A.S.
Head and Neck Cancer
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine.
- Trial name
- NCT00004062
- Testing
- azacitidine, liothyronine sodium, iodine I 131
- Where
- United States
- Sponsor
- Lucille P. Markey Cancer Center at University of Kentucky
Nasopharyngeal Carcinoma
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
Study Objective: Primary 1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with…
- Trial name
- NCT01326559
- Testing
- Docetaxel, Cisplatin, 5-FU and Cetuximab
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Papillary Thyroid Carcinoma
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?
study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection.
- Trial name
- NCT04336696
- Testing
- Total thyroidectomy and central neck dissection
- Where
- Egypt
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bassem Mohamed Sieda
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05898256
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Guangxi Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.